Objective: We investigated whether chondrocytes derived from osteoarthritic cartilage may lose their responsiveness to cartilage-derived morphogenetic protein-1, -2 (CDMP-1, -2) and osteogenic protein-1 (OP-1) compared with healthy cells, thus leading to an impaired maintenance of matrix integrity.
Introduction
Articular cartilage is a unique connective tissue that provides mechanical resistance to compression and shear forces as well as smooth and frictionless joint movement. These functions are essentially dependent on a precisely balanced physiological steady state between matrix degradation and replenishment. In osteoarthritis (OA), the most common rheumatic disease 1 , this metabolic equilibrium is compromised, thus causing a progressive loss of extracellular cartilaginous matrix that leads to a disruption of the cartilage integrity, and subsequently to a destruction of the joint surface 2 . Although the understanding of the pathogenesis of OA has evolved considerably over the past years, the molecular mechanisms are still not clear. In theory, a failure of cartilage homeostasis, such that anabolic processes become relatively deficient in comparison with catabolic ones may be viewed as the final pathway common to different causes 3 .
Polypeptide growth factors are actively involved in regulating matrix production and repair 4, 5 . Since they can also inhibit catabolic processes, a loss in chondrocytes' responsiveness to growth factor stimulation may be an important factor in the development of OA. Among the growth factors involved in cartilage metabolism, cartilage-derived morphogenetic proteins-1 and -2 (CDMP-1 and CDMP-2), the respective human homologs of mouse growth/ differentiation factors-5 and -6, may be of importance for cartilage maintenance and repair. These morphogens are members of the large transforming growth factor-(TGF-) superfamily and they are closely related to the bone morphogenetic protein (BMP) subgroups BMP-5/BMP-6/ osteogenic protein-1 (OP-1) and BMP-2/BMP-4. Both growth factors, first simultaneously and independently described by Chang et al. and Storm et al., are essential for the formation of cartilaginous tissue during embryonic limb development [6] [7] [8] . CDMP-1 and CDMP-2 exert their biological effects through binding to a heteromeric receptor complex of type I (preferentially BMP-receptor Ib or ALK-6) and type II serine/threonine kinase receptors 9, 10 . CDMP-1 is predominantly expressed at the stage of pre-cartilaginous mesenchymal condensations, subsequently around the cartilaginous cores of developing long bones, but most strikingly it is an excellent marker for the joint interzone 11 . CDMP-2 was found in different locations but mostly restricted to hypertrophic chondrocytes of ossifying long bone centers 6 . The physiological role of CDMP-1 has been established by its linkage to skeletal disorders, Hunter-Thompson chondrodysplasia, Grebe chondrodysplasia and brachydactyly [12] [13] [14] and thus provide evidence for the crucial involvement of CDMP-1 in human embryonic limb patterning and development. However, the role of CDMP-1 and CDMP-2 in post-natal cartilage is largely unknown.
In the present study we investigated the stimulatory effects of CDMP-1, CDMP-2 as well as OP-1 on matrix macromolecule synthesis, glycosaminoglycan (GAG) synthesis respectively, in post-natal human articular chondrocytes derived from healthy and osteoarthritic joints. We hypothesized that a loss of responsiveness to the indicated growth factors may be associated with an impaired matrix maintenance in osteoarthritic cartilage compared to healthy cells. Our findings demonstrate that CDMP-1, CDMP-2 and OP-1 increase the GAG biosynthetic activity of postnatal human articular chondrocytes independent of underlying OA disease. Furthermore the endogenous expression of CDMPs/OP-1 as well as their respective receptors was shown in both, healthy and osteoarthritic tissue.
Materials and Methods

GROWTH FACTORS
CDMP-1, CDMP-2 and OP-1 were kindly provided by Stryker Biotech (Hopkinton, MA, USA). Aliquots were stored at −80°C.
CELL CULTURE
Human articular cartilage from 17 patients (aged 37 to 80 years; mean age: 58.6 years) without macroscopic osteoarthritic lesions were obtained from surgical specimens at the time of endoprosthetic replacement for acute transcervical fractures and from organ donors. The removal of cartilage from organ donors was approved by the ethics committee of the University of Vienna. Osteoarthritic cartilage samples were obtained from 13 individuals, who underwent surgery for total hip endoprosthesis. The age of the patients ranged from 35 to 84 years with a mean age of 58.8 years.
Cartilage slices were aseptically dissected from the load-bearing joint surfaces, avoiding neocartilage at the margins of OA specimens, and finely minced. Chondrocytes were released by overnight digestion in 0.2% collagenase B (Boehringer Mannheim, Mannheim, Germany) at 37°C in a shaking waterbath. An aliquot of 50 l of the isolated cells was stained with 50 l Trypanblue for viability assessments.
Isolated cells were grown as monolayer cultures in a 1:1 mixture of Dulbecco's Modified Eagle's Medium (DMEM 25 mM Hepes+4500 mg/l glucose+pyridoxine, without sodium pyruvate; Life Technologies, Gaithersburg, MD, U.S.A.) and Ham's F12 (Ham's F-12+L-glutamine; Life Technologies) containing 10% (v/v) FBS (PAA Laboratories, Linz, Austria) and antibiotics/antimycotics (100 U/ml penicillin G, 100 mg/ml streptomycin, and 0.25 g/ml amphotericin B; Life Technologies). For GAG synthesis and cell proliferation assays, primary chondrocytes were plated in 24 multiwell-plates (Costar, Cambridge, MA, U.S.A.) in quadruplicates at a density of 2×10 5 cells/well. At 90% confluence chondrocyte cultures were switched to a recently described chemically defined serum free basal medium (BM) 9 . Over a period of 7 days growth factors and BM were added as needed and culture medium was replaced every second day. Cultures were maintained at 37°C in humidified air and 5% CO 2 .
For total RNA preparation, 2×10 6 primary cells were seeded in 100 mm tissue-culture dishes (Costar) and cultured as described above.
PROTEIN CONTENT
At the end of the 7-day stimulation period chondrocytes were suspended in 0.5 ml/well PBS (phosphate-buffered saline; GibcoBRL, Life Technologies, Paisley, Scotland) containing 0.05% (v/v) Triton X-100. Cells were disrupted by ultrasound (Vibra Cell ; Sonics & Materials Inc.; Danbury, CT, U.S.A.) and aliquots were transferred to 96-well plates (Costar). Two hundred l chromogenous solution (Bio-Rad Protein Assay; Bio Rad Laboratories GmbH, Munich, Germany) were added and samples were measured using an ELISA-Reader (Dynatch MR 7000; Guernsey, Channel Islands, U.K.).
BIOSYNTHESIS OF MACROMOLECULES
GAG synthesis rate, as determined by [ 35 S]sulfate incorporation into sulfated macromolecules, was evaluated as previously described 15 . Briefly, cells were labeled with 20 Ci/ml of [ 35 S]sulfate (carrier-free, Amersham Pharmacia Biotech, Uppsala, Sweden) for 6 hours at 37°C in serum-free BM. Cultures were extracted in guanidine-HCl buffer (4 M guanidine-HCl, 50 mM sodium acetate buffered at pH 7.2, in the presence of protease inhibitors). Unincorporated isotope was removed using Sephadex G-25 (PD-10 columns; Amersham Pharmacia Biotech) gel filtration chromatography in the guanidine-HCl buffer. Aliquots from void volume fractions were measured by liquid scintillation counting (1410 liquid scintillation counter; Wallac Oy, Turku, Finland) and normalized for cellular protein content.
CELL PROLIFERATION
Cell proliferation was determined after a 7-day stimulation period by adding 1 Ci/ml of methyl-[ 3 H]Thymidine (Amersham Pharmacia Biotech) to the cultures for the last 24 h of the culture period. Cells were then washed twice with PBS, suspended in 0.05% Triton X-100 solution and transfered to a filter matrix. Radioactivity uptake was analysed in a scintillation counter (1205 Betaplate : Wallac Oy, Turku, Finland). Positive controls (BM containing 10% FBS) were run in parallel.
RNA ISOLATION AND NORTHERN BLOT ANALYSIS
Total RNA was extracted using the modified acid guanidine-phenol-chloroform method established by Chomczynski and Sacchi 16 . For Northern blot analysis equal amounts (5 g) of total RNA, determined by A260, were electrophoresed on 1.2% agarose-formaldehyde gels and transferred onto Nytran membranes (Schleicher and Schuell, Keene, NH, U.S.A.). After UV cross-linking, the blots were pre-hybridized at 68°C for 30 min in hybridization buffer (Express Hyb, Clontech, Palo Alto, CA, U.S.A.), and hybridisation was performed with [ -32 P]deoxycytidine triphosphate-labeled (Amersham Pharmacia Biotech) cDNA fragments for 1 h at 68°C. cDNA fragments of aggrecan, type II collagen, and -actin (Table I) were amplified by RT-PCR, purified, and labeled using a random hexanucleotide-primed second-strand synthesis method. Membranes were subsequently washed three times in 2×saline-sodium citrate (SSC), 0.05% sodium dodecyl sulfate (SDS), twice in 0.2×SSC, 0.1% SDS at room temperature for 10 min and then exposed to Kodak XAR-5 film at −70°C for up to 24 h. Densitometry analysis was performed using 'Quantity One' software (Bio-Rad Laboratories, Hercules, CA, U.S.A.) and values were normalized for -actin content.
ANALYSIS OF CDMPS/BMP AND THEIR RESPECTIVE RECEPTORS
Total RNA of unstimulated chondrocyte cultures was extracted as described for Northern analysis, and 1 g of each sample was copied into cDNA in a 20 l reaction using the First-Strand cDNA Synthesis Kit (Amersham Pharmacia Biotech). One l aliquots were amplified in a 10 l reaction mixture that contained 50 mM Tris-HCl (pH 8.3), 2 mM MgCl 2 , 0.25% bovine serum albumin, 2.5% Ficoll 400, 5 mM tartrazine, 200 M of each dNTP, 1 M of each primer, and 0.2 U Taq polymerase (Boehringer Mannheim, Mannheim, Germany). The same reaction profile was used for all primer sets: an initial denaturation at 94°C for 1 min, followed by 30 cycles of 94°C for 1 s; 52-64°C for 1 s; and 72°C for 40 s, and an additional 2 min extension step at 72°C after the last cycle. Amplification reactions were performed in an air thermal cycler (Idaho Technology Inc., Idaho Falls, ID, U.S.A.). Primer sequences used are listed in Table I . Reaction products were analysed by electrophoresis in 1.5% agarose gels. The amplified DNA fragments were stained with SYBR-Green (Molecular Probes, Eugene, OR, U.S.A.) and visualized with a Fluorimager (Molecular Dynamics, Sunnyvale, CA, U.S.A.). Positive and negative controls were run in parallel.
WESTERN BLOT ANALYSIS
For Western blot analysis, chondrocytes from healthy and osteoarthritic joints were isolated and cultured in 24 multiwell plates (Costar) at a density of 2×10 5 cells/well, as described above until confluence. After washing the wells with PBS (GibcoBRL) three times, 50 l of sample buffer (NuPAGE LDS sample buffer (4×); Invitrogen Corporation; Carlsbad, CA, U.S.A.) per well were added. Cells were disrupted by ultrasound and samples were stored at −80°C.
For cartilage extraction, slices of freshly isolated articular cartilage (0.5 to 1 g wet weight) were washed with PBS, finely minced and extracted in guanidine-HCl buffer (1 M guanidine-HCl, 50 mM sodium acetate buffered at pH 7.2) in the presence of protease inhibitors for 3 h at 4°C and subsequently dialysed (Slide-A-Lyzer ® Dialysis Cassette; Pierce; Rockford, IL, U.S.A.) against water for 48 h at 4°C. Extracts were then lyophilized and resuspended in sample buffer (NuPAGE LDS sample buffer) to which 8 M urea was added and stored at −80°C.
Aliqots of samples (optimal volume of 1 l per lane was determined by sample dilution) were analysed under reduced conditions (10% dithioerythritol). Samples were boiled for 5 min in a water bath at 95°C and loaded onto a 10% Bis-Tris gel (NuPAGE 10% Bis-Tris Gel; Invitrogen Corporation). Electrophoresis was carried out in a commercially available running buffer (NuPAGE MOPS SDS running buffer (20×); Invitrogen Corporation) at 200 V for 50 min. Proteins were transferred from the gel onto a nitrocellulose membrane for 90 min at 30 V in a buffer containing 0.4 M Glycine, 0.5 M Tris base and 0.01 M SDS. Non-specific binding sites were blocked with 4% bovine serum albumin for 30 min. Blots were then probed with polyclonal antibodies against CDMP-1 and -2 20 and thereafter incubated with an appropriate horseradish peroxidase-conjugated secondary antibody (Jackson ImmunoResearch Laboratories Inc.; West Grove, PA, U.S.A.) at a dilution of 1:50,000. For detection enhancement 1 ml of a chemiluminescent substrate (SuperSignal ® West Pico Chemiluminescent Substrate; Pierce) was applied to the membrane. Recombinant CDMP-1 and -2 were used as positive controls, sample buffer served as negative control. Blots were visualized on Kodak X-Omat Aggrecan 17 5′-cgc tac gac gcc atc tgc tac-3′ 5′-gcc tgc tgt gcc tcc tca aa-3′ Type II collagen 17 5′-atg aca atc tgg ctc cca ac-3′ 5′-gcc cta tgt cca cac cga att-3′ -Actin 5′-tgt gat ggt ggg aat ggg tca g-3′ 5′-ttt gat gtc acg cac gat ttc c-3′ TGF-superfamily receptor type I (AKL-1) 18 5′-cga cgg agg cag gag aag cag-3′ 5′-tga agt cgc ggt ggg caa tgg-3′ Activin A receptor, type I (ALK-2) 18 5′-gag tga tga ttc ttc ctg tgc-3′ 5′-ttg gtg gtg atg agc cct tcg-3′ Bone morphogenetic protein receptor, type IA (ALK-3) 18 5′-aaa agt ggc ggt gaa agt att-3′ 5′-agt ctg gag gct gga ttg tgg-3′ Activin A receptor, type IB (ALK-4) 18 5′-gag atc gtg ggc acc caa ggg-3′ 5′-agc tgg gag agg gtc ttc ttg-3′ Transforming growth factor, beta receptor I (ALK-5) 18 5′-gat ggg ctc tgc ttt gtc tct-3′ 5′-tgt ctt tat tgt ctg ctg cta-3′ Bone morphogenetic protein receptor, type IB (ALK-6) 19 5′-tac aag cct gcc ata agt gag aag c-3′ 5′-atc atc gtg aaa caa tat ccg tct g-3′ BMPR-II (BMPR-II) 19 5′-tcc tct cat cag cca ttt gtc ctt tc-3′ 5′-agt tac tac aca ttc ttc ata g-3′ Activin type II receptor (ActR-II) 18 5′-gca aaa tga ata cga agt cta-3′ 5′-gca ccc tct aat acc tct gga-3′ Bone morphogenetic protein-7 (BMP-7/OP-1)
5′-atg gtg gct ttc ttc aag gc-3′ 5′-ttc agg atg acg ttg gag ct-3′ Cartilage-derived-morphogenetic Protein-1 (CDMP-1) 5′-acg gga cct gtt ctt taa tg-3′ 5′-ctt ata cac cac gtt gtt gg-3′ Cartilage-derived-morphogenetic Protein-2 (CDMP-2) 5′-gct ggg acg act gga tta tc-3′ 5′-tag acc aca tta ttg ccc gc-3′ 
Results
CDMPS/BMPS AND THEIR RESPECTIVE RECEPTORS ARE ENDOGENOUSLY EXPRESSED BY HEALTHY AND OSTEOARTHRITIC
CHONDROCYTES
To investigate whether postnatal human articular chondrocytes express CDMP-1, -2 and OP-1 as well as their respective cell surface receptors, RT-PCR analysis of total RNA obtained from cartilage of randomly selected patients with and without underlying OA was performed. When we examined the growth factor expression in these specimens, mRNAs encoding for CDMP-1, CDMP-2 could be detected [ Fig. 1(a) ]. RT-PCR of type I and type II receptors for CDMPs/BMPs yielded fragments specific for ALKs 1-6, ActR-II and BMPR-II in healthy as well as in osteoarthritic tissue samples [ Fig. 1(b) ].
In addition, to determine the presence of CDMP-1 and -2 protein in postnatal human articular cartilage derived from healthy and osteoarthritic joints by Western immunoblotting, we analysed both, cell lysates (data not shown) and cartilage extracts and demonstrated the presence of CDMP-1 and -2 in healthy as well as osteoarthritic cartilage. Recombinant proteins served as positive controls (Fig. 2) . Higher concentrations of CDMP-2 positive controls were used, since the recombinant protein is much less detectable then the native protein due to discrete protein sequence differences.
These data support a role of the indicated growth factors as autocrine/paracrine mediator(s) in cartilage matrix maintenance.
CDMPS STIMULATE SYNTHESIS OF MATRIX MACROMOLECULES IN
CHONDROCYTES DERIVED FROM HEALTHY AND OSTEOARTHRITIC CARTILAGE
A loss in the responsiveness of articular chondrocytes to relevant growth factors may result in an impairment of cartilage integrity. To obtain an insight into the pathogenic mechanisms leading to the development or progression of OA, we investigated whether chondrocytes derived from osteoarthritic cartilage lose their responsiveness to the cartilage-specific growth factors CDMP-1, CDMP-2, as well as OP-1 compared to healthy controls.
Optimal concentrations of 100 ng/ml for CDMP-1, -2 as well as OP-1, as previously shown by Erlacher et al. 20 and reconfirmed by dose/response analysis (data not shown), were used in all experiments. In healthy chondrocyte cultures, growth factor treatment resulted in an increase of [ 35 S]Sulfate incorporation into newly synthesized GAGs compared to cultures maintained in BM alone. This effect was observed for both CDMP-1 (181±15%; P<0.001) and CDMP-2 (150±13%; P<0.01). OP-1 was found to be twofold more stimulatory than CDMP-1 or CDMP-2 as determined by a 324±20% (P<0.001) increase in the [ 35 S]Sulfate incorporation rate [ Fig. 3(a) ].
The results obtained in osteoarthritic chondrocyte cultures also showed a significant increase of [ 35 S]Sulfate incorporation into newly synthesized matrix macromolecules in the presence of CDMP-1 (159±25%; P<0.05) CDMP-2 (120±23%; P<0.05) and OP-1 (226±28%; P<0.05) after 7 days in culture [ Fig. 3(b) ]. The comparison between healthy and osteoarthritic chondrocytes showed no significant difference between healthy and osteoarthritic tissue samples, neither for unstimulated nor stimulated cultures, suggesting no change in growth factor responsiveness in osteoarthritic cartilage.
NORTHERN BLOT ANALYSIS OF MRNA EXPRESSION OF AGGRECAN
AND COLLAGEN TYPE II
Further analysis of chondrocyte biosynthesis was performed using Northern blot analysis of the cartilage markers aggrecan and type II collagen. In both, healthy and osteoarthritic chondrocytes, cultured in the presence of the indicated growth factors, CDMP-1, CDMP-2 and OP-1 highly increased aggrecan mRNA levels, when densities of aggrecan mRNA bands were normalized to densities of -Actin bands (Fig. 4) . The expression of type II collagen mRNA was weak in both groups and not appreciably enhanced by either CDMP-1, CDMP-2 or OP-1 (data not shown).
To determine a possible stimulatory effect of CDMP-1 and CDMP-2 as well as OP-1 on cell proliferation, the rate of [ 3 H]Thymidine incorporation was assessed in healthy and osteoarthritic chondrocytes. Our data revealed that chondrocyte proliferation was not affected by growth factor treatment, either in healthy or in osteoarthritic cartilage (data not shown).
Discussion
This study compared the stimulatory effects of CDMP-1 and CDMP-2 on matrix macromolcule synthesis in healthy and osteoarthritic post-natal human articular chondrocytes. Furthermore, the endogenous expression profile of CDMPs/OP-1 and their respective receptors was investigated. We found no difference in GAG biosynthesis between healthy and osteoarthritic samples treated with CDMP-1 and CDMP-2 or OP-1. Moreover growth factors and their specific type-I and type-II receptors were endogenously expressed in cartilage with and without underlying OA disease. These findings suggest a potential role for the investigated growth factors, as anabolic mediators in the maintenance and repair of articular cartilage, both in postnatal healthy as well as osteoarthritic human cartilaginous tissue. It has been well established that members of the BMP family have the ability to increase cartilage matrix synthesis, as shown in chondrocyte cultures derived from animal and human articular cartilage 15, [22] [23] [24] [25] . However, studies on the stimulatory effects of CDMP-1 and CDMP-2 on cartilage metabolism are few. Erlacher and co-workers previously reported that these cartilage specific growth factors enhance GAG synthesis in fetal human and postnatal bovine articular chondrocytes 20 . However, the importance of CDMPs in mediating an up-regulation of matrix biosynthetic activity in adult human cartilage remains unclear. Our recent in vitro study showed the potential of CDMP-1 and CDMP-2 to increase the de novo GAG biosynthesis of postnatal human articular chondrocytes, as determined by [ 35 S]Sulfate incorporation into newly synthesized matrix macromolecules, supporting a role of CDMP-1 and CDMP-2 in the maintenance of cartilage homeostasis.
Moreover, CDMP-1 and CDMP-2 have been shown to increase matrix macromolecule synthesis by articular chondrocytes in an enzymatically depleted cartilage explant model 20 . In this regard we extended our observations by investigating the stimulatory effects of CDMP-1 and CDMP-2 on human articular chondrocytes derived from osteoarthritic joints, hypothesizing that a loss of responsiveness of osteoarthritic chondrocytes, compared to healthy cells, may disturb the equilibrium between anabolic and catabolic mediators and subsequently lead to metabolic deterioration of the cartilage matrix. This hypothesis was based on the findings of Doré and Tardif, who reported that osteoarthritic chondrocytes show a decrease in the responsiveness to insulin-like growth factor-I 26, 27 . In our culture settings we did not find any statistical difference in the rate of GAG synthesis between healthy and osteoarthritic samples, thus demonstrating no loss of responsiveness to CDMPs in osteoarthritic cartilage.
As shown by Brocklehurst and co-workers, who have consistently found no differences in GAG biosynthetic rate between OA and normal age-matched cartilage samples which were corrected for zonal and topographical cartilage surface sampling sites 28 , we did not find a difference in basal GAG synthesis between unstimulated healthy and osteoarthritic cartilage cultures. Our data strongly suggest that CDMP-1 and CDMP-2 contribute to the maintenance and repair not only in healthy but also in osteoarthritic post-natal human articular cartilage and further indicate that OA pathogenesis is not associated with a lack of response to CDMPs.
In recent years, an increasing number of autocrine or paracrine growth regulators have been identified in articular cartilage [29] [30] [31] . BMPs and their receptors were localized in mouse and rat epiphysial growth plate 32, 33 . Osteoarthritic chondrocytes have also been shown to express various growth factors including BMP-2 and TGF- 34, 35 . CDMP-1 and CDMP-2 mRNA was found in healthy bovine cartilage by Chang and co-workers using Northern blot analysis 6 . Beyond that, immunohistochemical staining revealed the presence of CDMP-1 and CDMP-2 in healthy as well as osteoarthritic human cartilage at the protein level 20 . This study extent these findings by Western immunoblotting and, to the best of our knowledge, it is the first study to examine the mRNA expression of CDMP-1 and CDMP-2 as well as their respective receptors in postnatal healthy and osteoarthritic human articular cartilage.
Our findings that healthy as well as osteoarthritic chondrocytes endogenously express CDMPs support their role in matrix maintenance. In addition, our study make these findings more biologically/functionally meaningful by demonstrating that independent of OA, post-natal human articular chondrocytes express BMP specific type I/type II serine/threonine kinase receptors. Surprisingly we found a lack of OP-1 mRNA in osteoarthritic tissue samples. In contrast to our data, Chubinskaya and co-workers, showed the presence of pro-and mature OP-1 in extracts of normal and osteoarthritic cartilages by Western blotting 36 . Our inability to detect OP-1 mRNA may be due to an extremely low level of the mRNA transcripts in osteoarthritic tissue which is beyond the limit of detection. This is consistent with the low levels of OP-1 mRNA detected in healthy cartilage samples. Another explanation may be the chondrocyte isolation and culture method that possibly Fig. 4 . Northern blot analysis on the expression of the extracellular matrix molecule aggrecan in healthy and osteoarthric cartilage. The figure shows a representative blot out of two experiments. Chondrocytes obtained from cartilage with and without osteoarthric lesions were cultured in basal medium (BM) in the presence or absence of CDMP-1 (100 ng/ml), CDMP-2 (100 ng/ml) and OP-1 (100 ng/ml) for 7 days. Equal amounts of total RNA from each culture (5 g) were separated on 1.2% agarose-formaldehyde gels, blotted and hybridized with complementary DNA probes for aggrecan as described in materials and methods. Hybridization with the reference probe -Actin to verify consistent loading of messenger RNA is shown at the bottom lane.
affects OP-1 expression, thereby not reflecting the in vivo situation. However, the mRNA expression of CDMPs/OP-1 and their respective receptors strongly suggest that these growth factors are involved in maintaining a physiological equilibrium of anabolic and catabolic mediators possibly in an autocrine/paracrine manner in post-natal human articular chondrocytes.
In conclusion, our findings demonstrate that CDMP-1 and CDMP-2 increase the GAG biosynthetic activity of post-natal human articular chondrocytes of healthy as well as osteoarthritic chondrocytes. Our conclusions are based on the measurement of matrix macromolecule synthesis, thus we cannot rule out other, differentially regulated effects of CDMP/OP-1 in osteoarthritic cartilage, such as collagen synthesis or matrix-metalloproteinase expression. However, as OA is not associated with a lack of growth factor expression/responsiveness in the resident cells, CDMPs/ OP-1 may not be critically involved in the progression of OA disease, but rather in the maintenance of tissue homeostasis.
